Last $61.01 USD
Change Today -1.10 / -1.77%
Volume 291.1K
RCPT On Other Exchanges
Symbol
Exchange
Frankfurt
As of 1:43 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

receptos inc (RCPT) Snapshot

Open
$61.72
Previous Close
$62.11
Day High
$62.48
Day Low
$59.64
52 Week High
09/29/14 - $67.35
52 Week Low
11/8/13 - $20.90
Market Cap
1.7B
Average Volume 10 Days
537.0K
EPS TTM
$-3.79
Shares Outstanding
27.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RECEPTOS INC (RCPT)

receptos inc (RCPT) Related Businessweek News

No Related Businessweek News Found

receptos inc (RCPT) Details

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics for immune disorders. Its lead product includes RPC1063, an oral sphingosine 1-phosphate 1 receptor modulator that is in Phase II portion of Phase II/III studies for the treatment of relapsing multiple sclerosis; and is in Phase II studies to treat ulcerative colitis. The company is also developing RPC4046, a monoclonal antibody, which is in Phase II studies for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that are in preclinical studies for the treatment of Type 2 diabetes. The company was formerly known as Receptor Pharmaceuticals, Inc. and changed its name to Receptos, Inc. in May 2009. Receptos, Inc. was founded in 2008 and is headquartered in San Diego, California.

47 Employees
Last Reported Date: 08/12/14
Founded in 2008

receptos inc (RCPT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $451.6K
Co-Founder and Chief Scientific Officer
Total Annual Compensation: $231.1K
Chief Financial Officer
Total Annual Compensation: $254.8K
Chief Medical officer
Total Annual Compensation: $364.3K
Compensation as of Fiscal Year 2013.

receptos inc (RCPT) Key Developments

Receptos, Inc. - Special Call

To discuss the results of positive phase 2 trial of RPC1063 in Relapsing Multiple Sclerosis

Receptos, Inc. Announces Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014

Receptos, Inc. announced consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported collaborative revenue of $1,100,000 against $1,238,000 a year ago. Loss from operations was $23,071,000 against $9,792,000 a year ago. Net loss attributable to common stockholders was $23,154,000 or $1.04 per basic and diluted share against $9,918,000 or $0.98 per basic and diluted share a year ago. The decrease in collaborative revenues during 2014 in comparison to the prior year reflects the termination of R&D funding from Ono in connection with the December 2013 amendment of agreement with them. For the six months, the company reported collaborative revenue of $2,450,000 against $2,726,000 a year ago. Loss from operations was $44,487,000 against $17,386,000 a year ago. Net loss attributable to common stockholders was $44,654,000 or $2.06 per basic and diluted share against $19,567,000 or $3.27 per basic and diluted share a year ago.

Receptos, Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-03-2014

Receptos, Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-03-2014 . Venue: The Mandarin Oriental Boston, 776 Boylston Street, Boston, MA 02119, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RCPT:US $61.02 USD -1.09

RCPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RCPT.
View Industry Companies
 

Industry Analysis

RCPT

Industry Average

Valuation RCPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 315.6x
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 307.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECEPTOS INC, please visit www.receptos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.